Get notified of page updates

Enroll in Research > Research Search & Enroll Tool > Treating Metastatic Prostate Cancer with a New PARP Inhibitor AZD5305 Combined With Hormone Therapy

Glossary on

off

Printer Friendly Page

Treating Metastatic Prostate Cancer with a New PARP Inhibitor AZD5305 Combined With Hormone Therapy

Clinicaltrials.gov identifier:
NCT05367440

Treatment
Treatment study for metastatic prostate cancer

Study Contact Information:

For additional information, please contact:

AstraZeneca Clinical Study Information Center

1-877-240-9479 [email protected]

Treating Metastatic Prostate Cancer with a New PARP Inhibitor AZD5305 in Combination With Hormone Therapy (PETRANHA)

About the Study

The current standard treatment for prostate cancer is the use of hormone therapy. This study will look at the effectiveness of a new drug called AZD5305 in combination with different hormone therapies to treat prostate cancer, compared to the current standard treatment. The goal of the study is to determine if the addition of the study drug AZD5305 is safe and effective at stopping the growth of prostate cancer.

What the Study Involves

There are two phases to the study, a dose escalation phase and an expansion phase. For each phase, people enrolled in the study will be assigned to one of several different groups. Participants in all groups will receive AZD5305 orally and one of the following oral hormone therapies:

(Xtandi)
Acetate (Zytiga)
Darolutamide (Nubeqa)
Apalutamide (Erleada)

People enrolled will be monitored for tumor growth and other outcomes. They will continue with both medications daily until disease worsens or they withdraw from the study.

Michigan

City: Detroit RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

New York

City: Syracuse RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

South Carolina

City: Myrtle Beach RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Texas

City: Houston RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Other Countries

Country: Australia
City: Camperdown RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Darlinghurst RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: East Melbourne RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Heidelberg RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Melbourne RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: St. Leonards RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Italy
City: Candiolo RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Italy
City: Milano RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Italy
City: Orbassano RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Italy
City: Padova RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Italy
City: Pavia RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Cambridge RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Glasgow RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Manchester RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Plymouth RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

This Study is Open To:

People, 18 years or older, who meet the following:

diagnosis of prostate cancer
- Phase 1: people with castration-sensitive or will be eligible.
- Phase 2: only people with will be eligible.
must be eligible for hormone therapy medication.
have a life expectancy of more than 16 weeks.
must be at least 4 weeks out from surgery or radiation.

This Study is Not Open To:

People will not be eligible to participate if:

they have previously received treatment with:
- a .
- any of the following hormonal therapies: Xtandi (), Zytiga ( acetate), Nubeqa (darolutamide) or Erleada (apalutamide).
- lutetium (Lu-PSMA)
- platinum chemotherapy